Supplementary Information (SI) for Organic & Biomolecular Chemistry. This journal is © The Royal Society of Chemistry 2024

Indoline Hemiaminals: A Platform for Accessing Anthranilic Acid Derivatives through Oxidative Deformylation

Keisuke Tokushige,^a Yuito Kobori,^a Shota Asai^b and Takumi Abe*^a

^aGraduate School of Medicine, Dentistry and Pharmaceutical Sciences,
 Okayama University, 1-1-1, Tsushima-naka, Kita-ku, Okayama 7008530, Japan E-mail: t-abe@okayama-u.ac.jp
 ^bSchool of Pharmacy,
 Shujitsu University, 1-6-1, Nishigawara, Naka-ku, Okayama 7038516, Japan

Supporting Information

General methods	S2
Optimization of reaction conditions (Table S1)	S3
Experimental procedures and spectra data for obtained products	·····S4–S36
References	S37
¹ H and ¹³ C NMR spectra ·····	······S38–S135

General methods. Column chromatography was carried out using silica gel (WAKO Gel 75–150 mesh, WAKO Co., Ltd.). Preparative tin-layer chromatography was performed with silica gel plates (60F-254). Melting points (mp) were recorded with a Yamato melting point apparatus model MP-21 and are uncorrected. IR spectra were measured with a HORIBA fourier transform infrared spectrometer FT-720, and absorbance frequencies are reported in reciprocal centimeters (cm⁻¹). NMR experiments were performed with JEOL JNM-ECZ600R (¹H NMR: 600 MHz, ¹³C NMR: 151 MHz) spectrometer. Chemical shifts are expressed in δ (parts per million, ppm) calues, and coupling constants are expressed in herts (Hz). ¹H NMR spectra were referenced to a solvent signal (CDCl₃: 7.26 ppm, DMSO-*d*₆: 2.50 ppm). ¹³C NMR spectra were referenced to a solvent signal (CDCl₃: 77.1 ppm, DMSO-*d*₆: 39.5). Signal multiplicities are abbreviated as follows: singlet (s), doublet (d), triplet (t), quartet (q), multiplet (m), doublet of doublets (dd), doublet of doublets (dd) septet (sept), broad (br). High-resolution MS spectra were recorded with a Brucker microTOF mass spectrometers (ESI-TOF-MS). Reactions were monitored by thin layer chromatography (TLC) carried out on a silica gel plates (60F-254) and visualized under UV illumination at 254 or 365 nm depending on the compounds.

 Table S1. Optimization of reaction conditions^{a [1]}



Entry	Additive	solvent	Yield (%) of 9aa ^b	Yield (%) of 10aa ^b
1	<i>tert</i> -BuOK	THF	81	3
2	<i>tert</i> -BuOK	toluene	75	1
3	<i>tert</i> -BuOK	MeCN	66	5
4	<i>tert</i> -BuOK	MeOH	65	0
5	<i>tert</i> -BuOK	CH_2CI_2	71	0
6	<i>tert</i> -BuOK	DMF	76	4
7	<i>tert</i> -BuOK	DMSO	81	3
8 ^c	<i>tert</i> -BuOK	DMSO	61	3
9 ^d	<i>tert</i> -BuOK	DMSO	72	2
10 ^e	<i>tert</i> -BuOK	DMSO	49	0
11 ^f	<i>tert</i> -BuOK	DMSO	1	0
12 ^g	<i>tert</i> -BuOK	DMSO	trace	0
13 ^{<i>h</i>}	<i>tert</i> -BuOK	DMSO	80	0
14	<i>tert</i> -BuONa	DMSO	79	0
15	<i>tert</i> -BuOLi	DMSO	60	0
16	NaOH	DMSO	80	0
17	КОН	DMSO	77	0
18	K ₂ CO ₃	DMSO	24	4
19	CsCO ₃	DMSO	74	0
20	Et ₃ N	CH_2CI_2	trace	-
21	none	DMSO	0	0

^{*a*} Reaction condition: 1aa (1.0 mmol) and additive in solvent (5 mL, 0.2 M) under Air. ^{*b*} Isolated yield. ^{*c*} Using 5 equiv. of *tert*-BuOK. ^{*d*} Using 2 equiv. of *tert*-BuOK. ^{*e*} Using 1 equiv. of *tert*-BuOK. ^{*f*} Under argon. ^{*g*} The reaction was performed in DMSO with FTP cycling under argon. ^{*h*} Under O₂ (1 atm).

Synthesis of N-protected indoles S1

The *N*-potected indoles **S1** as *N*-tosylindoles (**S1a**, **S1e–S1k**), *N*-benzenesulfonylindole (**S1b**), *N*-(4-methoxybenzenesulfonyl)indole (**S1c**), *N*-mesylindole (**S1d**) and *N*-(4-phenylbenzenesulfonyl)indole (**S1l**) were prepared by reported method.^[2] All substrates were used as received from commercial suppliers (Sigma-Aldrich, Kanto Chemical, TCI, Wako and Nacalai tesque) and all reagents were weighed and handled in air at room temperature. Analytical data are in accordance with the literature values.^[2]



Figure S1.



1-([1,1'-Biphenyl]-4-ylsulfonyl)-1*H***-indole (S11).^[2]** To a solution of indole (1.17 g, 10 mmol) and tetrabutylammonium bromide (161 mg, 0.05 equiv., 0.5 mmol) in toluene (10 mL, 0.1 M) were added NaOH (4.00 g, 10equiv., 0.10 mol) and H₂O (8.0 mL). The solution was stirred at room temperature for 15 minutes, biphenyl sulfonyl chloride (2.78 g, 1.1 equiv., 11 mmol) was added to the solution. After the solution was stirred further 12 h, H₂O (50 mL) was added to the mixture. The whole was extracted with AcOEt (3 x 50 mL). The combined organic layer was washed with brine (50 mL), dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography using hexane/AcOEt (5/1 v/v) to give **S11**.

White solid (2.07 g, 62% yield; mp 105–108 °C). IR (KBr) v: 3392, 3369, 1361, 1166, 761 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 8.04 (d, *J* = 8.4 Hz, 1H), 7.94 (d, *J* = 8.4 Hz, 2H), 7.62 (d, *J* = 8.4 Hz, 2H), 7.61 (d, *J* = 4.2 Hz, 1H), 7.55 (d, *J* = 7.8 Hz, 1H), 7.50 (d, *J* = 7.2 Hz, 2H), 7.43 (dd, *J* = 7.2, 7.2 Hz, 2H), 7.39 (dd, *J* = 7.8, 7.8 Hz, 1H), 7.34 (ddd, *J* = 7.8, 7.8, 0.6 Hz, 1H), 7.24 (ddd, *J* = 7.8, 7.8, 0.6 Hz, 1H), 6.69 (dd, *J* = 3.6, 0.6 Hz, 1H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 146.9, 139.0, 136.8, 135.0, 130.9, 129.2, 128.8, 128.0, 127.45, 127.45, 126.5, 124.8, 123.5, 121.6, 113.7, 109.4. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₀H₁₅NO₂SNa 356.0721; Found 356.0720.

Synthesis of trans-2-hydroxyindoline-3-trirthylammonium bromide (HITAB) S2

The *trans*-2-hydroxyindoline-3-triethylammonium bromides (HITAB) **S2** were prepared by reported method.^[3] All reagents were weighed and handled in air at room temperature. Analytical data are in accordance with the literature values (S2a^[3a], S2b, S2g, S2i^[3b], S2c, S2d^[3c], S2e, S2f^[3d]).



Figure S2.

Synthesis of indoline hemiaminals 8

The indoline hemiaminals **8** were prepared by reported method.^[1b, 3, 4] All reagents were weighed and handled in air at 80 °C. Analytical data are in accordance with the literature values.(8aa ^[3a], 8ba–8ga, 8ia, 8ka ^[3c], 8ab, 8ac, 8ae, 8ah–8al, 8ar, 8as ^[1b], 8ag ^[4])



Figure S3.



(*rac*)-*trans*-4-Chloro-3-(methyl(phenyl)amino)-1-tosylindolin-2-ol (8ha).^[4] To a solution of S1h (1.22 mg, 2 equiv., 10 mmol) and H₂O (1.8 mL, 20 equiv., 0.1 mol) in acetone (50 mL, 0.2 M) was added NBS (1.98 g, 2.2 equiv., 11 mmol). The mixture was stirred at room temperature for 15 h. Then Et₃N (1.54 mL, 2.2 equiv., 11 mmol) was added to the mixture and stirred further 1 h. The mixture was concentrated *in vacuo*. The residue was dissolved in AcOEt (50 mL, 0.1 M) and added *N*-methylaniline (0.54 mL, 5.0 mmol) and Et₃N (1.39 mL, 2.0 equiv., 10 mmol). The mixture was stirred at 80 °C in oil bath for 23 hours. After the whole was cooled to room temperature, H₂O (50 mL) was added to the mixture. The whole was extracted with AcOEt (3 x 50 mL). The combined organic layer was washed with brine (50 mL), dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography using hexane/AcOEt (3/1 v/v) to give **8ha**.

Blue solid (2.14 g, quant.; mp 154–156 °C). IR (KBr) v: 3482, 3093, 3058, 3025, 2948, 2827, 1598, 1450, 1342, 1157, 754 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 7.75 (d, *J* = 8.4 Hz, 2H), 7.57 (d, *J* = 7.8 Hz, 1H), 7.31 (dd, *J* = 8.4, 8.4 Hz, 1H), 7.27–7.24 (m, 4H), 7.05 (d, *J* = 8.4 Hz, 1H), 6.85 (d, *J* = 8.4 Hz, 2H), 6.80 (dd, *J* = 7.2, 7.2 Hz, 1H), 5.59 (d, *J* = 1.2 Hz, 1H), 5.14 (d, *J* = 1.2 Hz, 1H), 3.62 (br s, 1H), 2.39 (s, 3H), 1.94 (s, 3H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 148.9, 145.1, 142.4, 135.4, 133.0, 131.5, 130.2, 129.3, 127.1, 125.8, 124.8, 118.0, 113.5, 112.8, 91.0, 67.1, 32.1, 21.7. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₂H₂₁N₂O₃SNa 451.0859, 453.0830; Found 451.0855, 453.0828.



(*rac*)-*trans*-7-Chloro-3-(methyl(phenyl)amino)-1-tosylindolin-2-ol (8ja).^[4] To a solution of S1j (917 mg, 2 equiv., 3 mmol) and H₂O (0.54 mL, 20 equiv., 30 mmol) in acetone (15 mL, 0.2 M) was added NBS (587 mg, 2.2 equiv., 3.3 mmol). The mixture was stirred at room temperature for 9 h. Then Et₃N (0.46 mL, 2.2 equiv., 3.3 mmol) was added to the mixture and stirred further 1 h. The mixture was concentrated *in vacuo*. The residue was dissolved in AcOEt (15 mL, 0.1 M) and added *N*-methylaniline (161 mg, 1.5 mmol) and Et₃N (0.42 mL,

2.0 equiv., 3 mmol). The mixture was stirred at 80 °C in oil bath for 6 hours. After the whole was cooled to room temperature, H_2O (20 mL) was added to the mixture. The whole was extracted with AcOEt (3 x 20 mL). The combined organic layer was washed with brine (20 mL), dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography using hexane/AcOEt (3/1 v/v) to give **8ja**.

White solid (391 mg, 61% yield; mp 134–136 °C). IR (KBr) v: 3423, 3064, 2979, 2923, 2813, 1600, 1506, 1461, 1328, 1147, 775 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 7.89 (d, *J* = 8.4 Hz, 1.7H), 7.74 (d, *J* = 7.8 Hz, 0.30H), 7.34–7.25 (m, 5H), 7.19 (d, *J* = 7.2 Hz, 0.85H), 7.14 (dd, *J* = 7.8, 7.8 Hz, 0.15H), 7.08 (dd, *J* = 7.8, 7.8 Hz, 0.85H), 7.01 (d, *J* = 8.4 Hz, 1.85H), 6.87 (dd, *J* = 7.2, 7.2 Hz, 0.85H), 6.81 (dd, *J* = 7.2, 7.2 Hz, 0.15H), 6.64 (d, *J* = 8.4 Hz, 0.30H), 6.21 (s, 0.85H), 6.12 (d, *J* = 5.4 Hz, 0.15H), 5.09 (s, 0.85H), 5.03 (d, *J* = 6.0 Hz, 0.15H), 3.63 (br s, 0.85H), 3.22 (br s, 0.15H), 2.80 (s, 0.45H), 2.61 (s, 2.55H), 2.44 (s, 0.45H), 2.43 (2.55H); ¹³C {¹H} NMR (151 MHz, CDCl₃) δ 149.5, 149.4, 144.7, 143.84, 143.84, 139.2, 138.9, 137.9, 136.9, 136.0, 133.0, 132.2, 131.2, 129.9, 129.61, 129.57, 129.50, 127.2, 127.0, 126.1, 126.0, 125.1, 123.9, 122.4, 118.7, 118.0, 114.3, 112.7, 90.6, 88.9, 67.3, 63.6, 36.0, 33.5, 21.8, 21.7. HRMS (ESI) *m*/*z*: [M+Na]⁺ Calcd for C₂₂H₂₁N₂O₃SNa 451.0859, 453.0830; Found 451.0855, 453.0830.



(*rac*)-*trans*-3-((3-Chlorophenyl)(methyl)amino)-1-tosylindolin-2-ol (8ad).^[3a] To a suspension of S2a (582 mg, 1.2 equiv., 1.2 mmol) in AcOEt (10 mL, 0.1 M) were added *m*-chloro-*N*-methylaniline (142 mg, 1.0 mmol) and Et₃N (0.26 mL, 2 equiv., 2.0 mmol). The suspension was stirred at 80 °C in oil bath for 2 h. After the whole was cooled to room temperature, H₂O (10 mL) was added to the mixture. The whole was extracted with AcOEt (3 x 10 mL). The combined organic layer was washed with brine (10 mL), dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography using hexane/AcOEt (2/1 v/v) to give **8ad**.

Purple oil (368 mg, 86% yield; mp 180 °C). IR (KBr) v: 3471, 3064, 2948, 2900, 2817, 1592, 1496, 1346, 1160, 759 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 7.74 (d, *J* = 8.4 Hz, 2H), 7.65 (d, *J* = 7.2 Hz, 1H), 7.36 (ddd, *J* = 7.8, 7.8, 1.2 Hz, 1H), 7.25 (d, *J* = 8.4 Hz, 2H), 7.14 (dd, *J* = 8.4, 8.4 Hz. 1H), 7.11 (d, *J* = 7.2 Hz, 1H), 7.08 (dd, *J* = 7.8, 7.8 Hz, 1H), 6.84 (dd, *J* = 2.4, 2.4 Hz. 1H), 6.80 (dd, *J* = 8.4, 2.4 Hz, 1H), 6.77 (dd, *J* = 8.4, 1.2 Hz, 1H), 5.54 (d, *J* = 3.0 Hz, 1H), 5.15 (d, *J* = 2.4 Hz, 1H), 3.87 (br s, 1H), 2.38 (s, 3H), 1.91 (s, 3H); ¹³C {¹H} NMR (151 MHz, CDCl₃) δ 150.5, 144.9, 140.9, 135.3, 135.2, 130.3, 130.3, 130.1, 127.4, 127.1, 126.3, 124.5, 118.2, 114.5, 113.9, 112.1, 90.2, 67.3, 33.0, 21.7. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₂H₂₁ClN₂O₃SNa 451.0859, 453.0830; Found 451.0860, 453.0835.



(*rac*)-*trans*-3-Morpholino-1-tosylindolin-2-ol (8af).^[3a] To a suspension of S2a (582 mg, 1.2 equiv., 1.2 mmol) in AcOEt (10 mL, 0.1 M) were added morpholine (87 mg, 1.0 mmol) and Et₃N (0.26 mL, 2 equiv., 2.0 mmol). The suspension was stirred at 80 °C in oil bath for 2 h. After the whole was cooled to room temperature, H₂O (10 mL) was added to the mixture. The whole was extracted with AcOEt (3 x 10 mL). The combined organic layer was washed with brine (10 mL), dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography using hexane/AcOEt (2/1 v/v) to give **8af**.

White solid (276 mg, 74% yield; mp 164 °C). IR (KBr) v: 3336, 2969, 2921, 2871, 2819, 1596, 1463, 1353, 1174, 1106, 765 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 7.75 (d, J = 7.8 Hz, 2H), 7.57 (d, J = 8.4 Hz, 1H), 7.29 (dd, J = 7.8, 7.8 Hz, 1H), 7.26 (d, J = 7.8 Hz, 1H), 7.23 (d, J = 7.8 Hz, 2H), 7.05 (ddd, J = 7.2, 7.2, 0.6 Hz, 1H), 5.68 (d, J = 2.4 Hz, 1H), 4.07 (br s, 1H), 4.03 (d, J = 1.8 Hz, 1H), 3.49–3.46 (m, 2H), 3.44–3.40 (m, 2H), 2.34 (s, 3H), 2.15 (br s, 2H), 2.01 (br s, 2H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 1144.7, 140.9, 135.4, 129.95, 129.85, 127.6, 127.1, 126.8, 124.0, 114.1, 85.5, 72.9, 67.0, 48.8, 21.6. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₁₉H₂₂N₂O₄SNa 397.1198; Found 397.1197.



(*rac*)-*trans*-3-(5-Bromo-1*H*-indol-3-yl)-1-tosylindolin-2-ol (8am).^[3a] To a suspension of S2a (1.65 g, 1.2 equiv., 3.6 mmol) in AcOEt (30 mL, 0.1 M) were added 5-bromoindole (595 mg, 3.0 mmol) and Et₃N (0.83 mL, 2 equiv., 6.0 mmol). The suspension was stirred at 80 °C in oil bath for 2 h. After the whole was cooled to room temperature, H_2O (10 mL) was added to the mixture. The whole was extracted with AcOEt (3 x 10 mL). The combined organic layer was washed with brine (10 mL), dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography using hexane/AcOEt (1/1 v/v) to give 8am.

Brown oil (1.02 g, 70% yield). IR (KBr) v: 3062, 2967, 2923, 1457, 1338, 1164, 750, 576 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 8.13 (br s, 1H), 7.59 (d, J = 7.8 Hz, 1H), 7.56 (d, J = 7.8 Hz, 2H), 7.28 (dd, J = 7.8, 7.8 Hz, 7.8 Hz,

1H), 7.23 (dd, J = 9.0, 1.8 Hz, 1H), 7.18–7.17 (m, 2H), 7.07 (d, J = 8.4 Hz, 2H), 7.04 (d, J = 7.8 Hz, 1H), 7.01 (dd, J = 7.2, 7.2 Hz, 1H), 6.34 (s, 1H), 5.75 (dd, J = 3.0, 3.0 Hz, 1H), 4.52 (d, J = 1.8 Hz, 1H), 3.94 (d, J = 3.0 Hz, 1H), 2.33 (); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 144.5, 140.0, 135.3, 134.5, 131.0, 129.8, 128.7, 127.6, 127.1, 125.9, 125.s, 3H4, 124.3, 124.0, 121.4, 114.6, 114.3, 113.1, 112.9, 93.0, 47.1, 21.8. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₃H₁₉BrN₂O₃SNa 505.0198, 507.0177; Found 505.0200, 507.0181.



(*rac*)-*trans*-3-(4-Chloro-1*H*-indol-3-yl)-1-tosylindolin-2-ol (8am).^[3a] To a suspension of S2a (1.65 g, 1.2 equiv., 3.6 mmol) in AcOEt (30 mL, 0.1 M) were added 4-chloroindole (455 mg, 3.0 mmol) and Et₃N (0.83 mL, 2 equiv., 6.0 mmol). The suspension was stirred at 80 °C in oil bath for 2 h. After the whole was cooled to room temperature, H₂O (10 mL) was added to the mixture. The whole was extracted with AcOEt (3 x 10 mL). The combined organic layer was washed with brine (10 mL), dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography using hexane/AcOEt (1/1 v/v) to give **8an**. Yellow oil (1.03 g, 78% yield). IR (KBr) v: 3029, 2967, 2925, 1475, 1340, 1166, 750 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 8.46 (br s, 0.2H), 7.86 (br s, 0.8H), 7.82 (d, *J* = 8.4 Hz, 0.4H), 7.56 (d, *J* = 8.4 Hz, 1.6H), 7.54–7.53 (m, 1H), 7.28–7.23 (m, 1.6H), 7.18 (d, *J* = 7.8 Hz, 1.6H), 7.13–7.00 (m, 5H), 6.17 (dd, *J* = 6.6, 4.8 Hz, 0.2H), 5.91 (s, 0.8H), 5.61 (br s, 0.8H), 5.45 (d, *J* = 6.6 Hz, 0.2H), 5.05 (s, 0.8H), 3.39 (br s, 0.8H), 2.83 (d, *J* = 4.8 Hz, 0.2H), 2.38 (s, 0.6H), 2.33 (s, 2.4H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 144.4, 143.9, 140.4, 140.0, 138.0, 136.2, 135.5, 132.6, 132.2, 129.8, 129.4, 128.6, 128.4, 127.3, 126.8, 126.6, 126.0, 125.8, 125.7, 124.2, 124.1, 123.0, 122.9, 121.0, 120.8, 115.8, 114.8, 114.7, 110.8, 110.2, 108.7, 93.2, 87.7, 47.3, 44.8, 21.63, 21.57. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₃H₁₉N₂O₃SNa 461.0703, 463.0673; Found 461.0702, 463.0669.



(*rac*)-*trans*-3-(6-Chloro-1*H*-indol-3-yl)-1-tosylindolin-2-ol (8ao).^[3a] To a suspension of S2a (1.65 g, 1.2 equiv., 3.6 mmol) in AcOEt (30 mL, 0.1 M) were added 6-chloroindole (455 mg, 3.0 mmol) and Et_3N (0.83 mL,

2 equiv., 6.0 mmol). The suspension was stirred at 80 °C in oil bath for 2 h. After the whole was cooled to room temperature, H_2O (10 mL) was added to the mixture. The whole was extracted with AcOEt (3 x 10 mL). The combined organic layer was washed with brine (10 mL), dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography using hexane/AcOEt (1/1 v/v) to give **8ao**.

Yellow oil (1.14 g, 86% yield). IR (KBr) v: 3384, 3064, 2965, 2877, 1596, 1459, 1340, 1166, 752, 578 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 8.01 (br s, 1H), 7.63 (d, *J* = 7.8 Hz, 1H), 7.60 (d, *J* = 8.4 Hz, 2H), 7.29–7.27 (m, 2H), 7.09 (d, *J* = 8.4 Hz, 2H), 7.03–6.98 (m, 2H), 6.74 (dd, *J* = 7.8, 1.8 Hz, 1H), 6.64 (d, *J* = 9.0 Hz, 1H), 6.48 (d, *J* = 2.4 Hz, 1H), 5.74 (d, *J* = 3.0 Hz, 1H), 4.53 (d, *J* = 3.0 Hz, 1H), 3.84 (br s, 1H), 2.37 (s, 3H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 144.6, 139.9, 137.1, 134.4, 131.3, 129.8, 128.7, 128.2, 127.2, 125.9, 124.34, 124.28, 123.6, 120.3, 119.6, 115.0, 114.2, 111.3, 92.9, 47.3, 21.7. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₃H₁₉ClN₂O₃SNa 461.0703, 463.0673; Found 461.0700, 463.0674.



(*rac*)-*trans*-3-(7-Chloro-1*H*-indol-3-yl)-1-tosylindolin-2-ol (8ap).^[4] To a suspension of S2a (1.65 g, 1.2 equiv., 3.6 mmol) in AcOEt (30 mL, 0.1 M) were added 7-chloroindole (455 mg, 3.0 mmol) and Et₃N (0.83 mL, 2 equiv., 6.0 mmol). The suspension was stirred at 80 °C in oil bath for 2 h. After the whole was cooled to room temperature, H₂O (10 mL) was added to the mixture. The whole was extracted with AcOEt (3 x 10 mL). The combined organic layer was washed with brine (10 mL), dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography using hexane/AcOEt (1/1 v/v) to give **8ap**. Pale-yellow oil (529 mg, 40% yield). IR (KBr) v: 3064, 2956, 2923, 1596, 1477, 1346, 1166, 754, 576 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 8.09 (br s, 1H), 7.66 (d, *J* = 8.4 Hz, 1H), 7.53 (d, *J* = 7.8 Hz, 2H), 7.30 (ddd, *J* = 7.8, 7.8, 0.6 Hz, 1H), 7.15 (dd, *J* = 7.2, 1.8 Hz, 1H), 7.05–7.01 (m, 4H), 6.78–6.76 (m, 2H), 6.43 (d, *J* = 2.4 Hz, 1H), 5.76 (dd, *J* = 3.0, 3.0 Hz, 1H), 4.54 (d, *J* = 3.0 Hz, 1H), 3.87 (d, *J* = 3.0 Hz, 1H), 2.37 (s, 3H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 144.4, 140.0, 134.6, 134.0, 131.3, 129.7, 128.7, 127.2, 127.1, 125.9, 124.4, 123.4, 121.8, 120.5, 117.6, 116.7, 116.3, 114.6, 92.8, 47.3, 21.7. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₃H₁₉ClN₂O₃SNa 461.0703, 463.0673; Found 461.0698, 463.0678.



(*rac*)-*trans*-1-([1,1'-Biphenyl]-4-ylsulfonyl)-3-(methyl(phenyl)amino)indolin-2-ol (8la).^[4] To a solution of S1I (1.00 g, 2 equiv., 3 mmol) and H₂O (0.54 mL, 20 equiv., 30 mmol) in acetone (15 mL, 0.2 M) was added NBS (587 mg, 2.2 equiv., 3.3 mmol). The mixture was stirred at room temperature for 21.5 h. Then Et₃N (0.46 mL, 2.2 equiv., 3.3 mmol) was added to the mixture and stirred further 1 h. The mixture was concentrated *in vacuo*. The residue was dissolved in AcOEt (15 mL, 0.1 M) and added *N*-methylaniline (161 mg, 1.5 mmol) and Et₃N (0.42 mL, 2.0 equiv., 3 mmol). The mixture was stirred at 80 °C in oil bath for 2 hours. After the whole was cooled to room temperature, H₂O (20 mL) was added to the mixture. The whole was extracted with AcOEt (3 x 20 mL). The combined organic layer was washed with brine (20 mL), dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography using hexane/AcOEt (3/1 v/v) to give **8la**.

White solid (623 mg, 91% yield; mp 167–169 °C). IR (KBr) v: 3467, 3064, 3029, 2950, 2817, 1600, 1504, 1355, 1164, 765, 609 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 7.92 (d, *J* = 8.4 Hz, 2H), 7.71 (d, *J* = 8.4 Hz, 1H), 7.66 (d, *J* = 9.0 Hz, 2H), 7.54 (d, *J* = 6.6 Hz, 2H), 7.47 (dd, *J* = 7.2, 7.2 Hz, 2H), 7.42 (dd, *J* = 7.2, 7.2 Hz, 1H), 7.38 (dd, *J* = 7.8, 7.8 Hz, 1H), 7.25 (dd, *J* = 7.2, 7.2 Hz, 2H), 7.15 (d, *J* = 7.8 Hz, 1H), 7.10 (ddd, *J* = 7.2, 7.2, 0.6 Hz, 1H), 6.89 (d, *J* = 8.4 Hz, 2H), 6.81 (dd, *J* = 7.2, 7.2 Hz, 1H), 5.62 (dd, *J* = 2.4, 2.4 Hz, 1H), 5.22 (d, *J* = 1.8 Hz, 1H), 3.74 (d, *J* = 2.4 Hz, 1H), 1.96 (s, 3H); ¹³C {¹H} NMR (151 MHz, CDCl₃) δ 149.3, 146.7, 140.8, 138.9, 136.8, 130.1, 129.5, 129.3, 128.9, 128.01, 128.01, 127.6, 127.4, 126.5, 124.5, 118.4, 114.5, 114.2, 90.2, 67.5, 33.1. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₇H₂₄N₂O₃SNa 479.1405; Found 479.1403.



(*rac*)-*trans*-3-(1*H*-indol-1-yl)-1-tosylindolin-2-ol (8aq).^[5] To a solution of 8ag (582 mg, 1 mmol) in benzene (5 mL, 0.2 M) was added DDQ (227 mg, 1.0 equiv., 1 mmol). The mixture was stirred at room temperature for 2 h. After the whole was quenched with sat. NaHCO₃ (5 mL), the mixture was extracted with AcOEt (3 x 20 mL). The combined organic layer was washed with brine (20 mL), dried over Na₂SO₄, filtered, and concentrated

in vacuo. The residue was purified by silica gel column chromatography using hexane/AcOEt (3/1 v/v) to give **8aq**.

Pale-brown oil (406 mg, quant). IR (KBr) v: 3048, 2923, 1596, 1457, 1353, 1166, 742, 576 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 7.76 (d, *J* = 8.4 Hz, 1H), 7.622–7.608 (m, 1H), 7.615 (d, *J* = 8.4 Hz, 2H), 7.44 (dd, *J* = 7.8, 7.8 Hz, 1H), 7.16–7.07 (m, 7H), 6.25 (d, *J* = 3.0 Hz, 1H), 6.08 (br s, 1H), 5.77 (d, *J* = 1.8 Hz, 1H), 5.65 (s, 1H), 4.03 (d, *J* = 2.4 Hz, 1H), 2.42 (s, 3H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 144.8, 141.3, 135.9, 134.8, 130.8, 130.1, 129.5, 127.1, 126.7, 126.6, 125.1, 124.7, 122.0, 121.2, 120.3, 115.0, 109.9, 102.4, 91.9, 64.1, 21.5. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₃H₂₀N₂O₃SNa 427.1092; Found 427.1088.

Scheme S1. C1 deletion reactions of indoline hemiaminals



General Procedure: To a solution of **8** (0.5 mmol) in DMSO (2.5 mL, 0.2 M) was added *tert*-BuOK (168.3 mg, 1.5 mmol, 3.0 equiv.) under air condition. The mixture was stirred at room temperature until the complete disappearance of starting materials as indicated by TLC. After $H_2O(20 \text{ mL})$ was added to the mixture, the whole was extracted with AcOEt (3 x 20 mL) and washed with brine (5 x 20 mL). The combined organic layer was dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography using hexane/AcOEt solvent mixture as the eluent.



N-Methyl-2-((4-methylphenyl)sulfonamido)-*N*-phenylbenzamide (9aa). The reaction was performed according to the general procedure used 394.5 mg (1 mmol) of 8aa. Purification by column chromatography on silica gel using hexane/AcOEt (2/1 v/v) to give 9aa.

Pale-yellow solid (308 mg, 81% yield; mp 179–180 °C). IR (KBr) v: 3226, 3062, 2983, 2958, 2917, 1623, 1583, 1484, 1369, 1166, 1089, 765, 563 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 9.33 (br s, 1H), 7.80 (d, *J* = 8.4 Hz, 2H), 7.65 (d, *J* = 8.4 Hz, 1H), 7.27 (d, *J* = 7.8 Hz, 2H), 7.16 (dd, *J* = 7.8, 7.8, 1.2 Hz, 1H), 7.09–7.04 (m, 3H), 6.66 (d, *J* = 7.8 Hz, 1H), 6.62 (dd, *J* = 7.2, 7.2 Hz, 1H), 6.35 (d, *J* = 6.0 Hz, 2H), 3.40 (s, 3H), 2.35 (s, 3H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 169.3, 144.3, 144.0, 137.4, 137.3, 131.0, 130.1, 129.8, 129.2, 127.6, 126.8, 126.3, 124.6, 123.0, 122.4, 38.5, 21.6. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₁H₂₀N₂O₃SNa 403.1092; Found 403.1091.



N-Methyl-*N*-phenyl-2-(phenylsulfonamido)benzamide (9ba). The reaction was performed according to the general procedure used 190 mg (0.5 mmol) of **8ba**. Purification by column chromatography on silica gel using hexane/AcOEt (2/1 v/v) to give **9ba**.

White solid (160 mg, 87% yield; mp 140–142 °C). IR (KBr) v: 3235, 3058, 2942, 1629, 1590, 1488, 1376, 1168, 752, 582 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 9.42 (br s, 1H), 7.91 (d, *J* = 7.2 Hz, 2H), 7.65 (dd, *J* = 8.4, 1.2 Hz, 1H), 7.55–7.52 (m, 1H), 7.48 (dd, *J* = 7.8, 7.8 Hz, 2H), 7.15 (dd, *J* = 7.8, 7.8 Hz, 1H), 7.07–7.04 (m, 3H), 6.66 (d, *J* = 7.2 Hz, 1H), 6.62 (dd, *J* = 7.2, 7.2 Hz, 1H), 6.34 (br s, 2H), 3.38 (s, 3H); ¹³C {¹H} NMR (151 MHz, CDCl₃) δ 169.2, 144.1, 140.3, 137.0, 133.2, 131.0, 130.1, 129.3, 129.2, 127.4, 126.8, 126.2, 124.6, 123.2, 122.5, 38.5. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₀H₁₈N₂O₃SNa 389.0936; Found 389.0932.



2-((4-Methoxyphenyl)sulfonamido)-*N***-methyl-***N***-phenylbenzamide (9ca).** The reaction was performed according to the general procedure used 205 mg (0.5 mmol) of **8ca**. Purification by column chromatography on silica gel using hexane/AcOEt (2/1 v/v) to give **9ca**.

White solid (185 mg, 93% yield; mp 120–122 °C). IR (KBr) v: 3280, 3056, 3008, 2975, 2940, 2902, 2840,1625, 1592, 1492, 1367, 1263, 1155, 755, 566 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 9.25 (br s, 1H), 7.84 (d, *J* = 7.8 Hz, 2H), 7.63 (d, *J* = 8.4 Hz, 1H), 7.14 (dd, *J* = 7.8, 7.8 Hz, 1H), 7.084–7.078 (m, 3H), 6.93 (d, *J* = 8.4 Hz, 2H), 6.68 (d, *J* = 7.8 Hz, 1H), 6.62 (dd, *J* = 7.2, 7.2 Hz, 1H), 6.46 (br s, 2H), 3.79 (s, 3H), 3.40 (s, 3H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 169.3, 163.3, 144.3, 137.4, 131.9, 131.0, 130.1, 129.6, 129.3, 126.8, 126.3, 124.5, 123.0, 122.2, 114.3, 55.7, 38.5. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₁H₂₀N₂O₄SNa 419.1042; Found 419.1038.



N-Methyl-2-(methylsulfonamido)-*N*-phenylbenzamide (9da). The reaction was performed according to the general procedure used 159 mg (0.5 mmol) of 8da. Purification by column chromatography on silica gel using hexane/AcOEt (2/1 v/v) to give 9aa.

Pale-yellow oil (65.7 mg, 43% yield). IR (KBr) v: 3262, 3064, 3029, 2931, 1627, 1592, 1494, 1330, 1155, 759, 700, 518 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 8.69 (br s, 1H), 7.55 (d, *J* = 8.4 Hz, 1H), 7.24 (dd, *J* = 7.8, 7.8 Hz, 2H), 7.21 (dd, *J* = 8.4, 8.4 Hz, 1H), 7.16 (dd, *J* = 7.2, 7.2 Hz, 1H), 7.03 (d, *J* = 7.8 Hz, 2H), 6.87 (d, *J* = 7.8 Hz, 1H), 6.72 (dd, *J* = 7.8, 7.8 Hz. 1H), 3.49 (s, 3H), 3.13 (s, 3H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 169.5, 144.3, 137.4, 131.1, 130.2, 129.6, 127.2, 126.5, 124.0, 122.7, 119.5, 40.4, 38.5. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₁₅H₁₆N₂O₃SNa 327.0779; Found 327.0779.



5-Methoxy-N-methyl-2-((4-methylphenyl)sulfonamido)-N-phenylbenzamide (9ea). The reaction was performed according to the general procedure used 212 mg (0.5 mmol) of **8ea**. Purification by column chromatography on silica gel using hexane/AcOEt (2/1 v/v) to give **9ea**.

Pale-brown solid (134 mg, 60% yield; mp 116–118 °C). IR (KBr) v: 3195, 3095, 3052, 3000, 2956, 2929, 2830,1621, 1589, 1496, 1367, 1268, 1160, 765, 701, 541 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 9.09 (br s, 1H), 7.76 (d, *J* = 7.8 Hz. 2H), 7.57 (d, *J* = 9.0 Hz, 1H), 7.27 (d, *J* = 9.0 Hz, 2H), 7.12–7.06 (m, 3H), 6.74 (dd, *J* = 9.0, 3.0 Hz, 1H), 6.26 (br s, 2H), 6.13 (br s, 1H), 3.38 (s, 3H), 3.28 (s, 3H), 2.34 (s, 3H); ¹³C {¹H} NMR (151 MHz, CDCl₃) δ 168.7, 155.3, 144.4, 144.0, 137.5, 130.2, 129.7, 129.3, 127.7, 126.9, 126.3, 125.6, 117.9, 114.4, 55.3, 38.5, 21.6. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₂, H₂₂N₂O₄SNa 433.1195; Found 433.1198.



5-Chloro-N-methyl-2-((4-methylphenyl)sulfonamido)-N-phenylbenzamide (9fa). The reaction was performed according to the general procedure used 214 mg (0.5 mmol) of **8fa**. Purification by column chromatography on silica gel using hexane/AcOEt (2/1 v/v) to give **9fa**.

Pale-brown solid (156 mg, 75% yield; mp 163 °C). IR (KBr) v: 3266, 3056, 2927, 2877, 1631, 1589, 1492, 1375, 1166, 1091, 767, 700, 570 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 9.19 (br s, 1H), 7.79 (d, *J* = 8.4 Hz, 2H), 7.60 (d, *J* = 8.4 Hz, 1H), 7.29 (d, *J* = 7.8 Hz, 2H), 7.16–7.10 (m, 4H), 6.61 (br s, 1H), 6.37 (br s, 2H), 3.40 (s, 3H), 2.37 (s, 3H); ¹³C {¹H} NMR (151 MHz, CDCl₃) δ 167.9, 144.3, 143.8, 137.2, 135.9, 131.0, 129.94, 129.94, 129.5, 128.7, 127.6, 127.4, 126.3, 125.9, 123.8, 38.5, 21.7. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₁H₁₉ClN₂O₃SNa 437.0703, 439.0673; Found 437.0701, 439.0678.



5-Bromo-*N***-methyl-2-((4-methylphenyl)sulfonamido)**-*N***-phenylbenzamide (9ga).** The reaction was performed according to the general procedure used 236 mg (0.5 mmol) of **8ga**. Purification by column chromatography on silica gel using hexane/AcOEt (2/1 v/v) to give **9ga**.

White solid (134 mg, 58% yield; mp 161–163 °C). IR (KBr) v: 3270, 3052, 3031, 2925, 2877, 1646, 1590, 1492, 1328, 1166, 1089, 763, 703, 578 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 9.20 (br s, 1H), 7.78 (d, *J* = 8.4 Hz, 2H), 7.54 (d, *J* = 9.0 Hz, 1H), 7.29 (d, *J* = 8.4 Hz, 2H), 7.26–7.25 (m, 1H), 7.15 (dd, *J* = 7.8, 7.8 Hz, 1H), 7.11 (dd, *J* = 7.2, 7.2 Hz, 2H), 6.76 (br s, 1H), 6.38 (br s, 2H), 3.39 (s, 3H), 2.37 (s, 3H); ¹³C {¹H} NMR (151 MHz, CDCl₃) δ 167.7, 144.3, 143.8, 137.1, 136.3, 133.8, 132.9, 129.9, 129.5, 127.6, 127.4, 126.3, 126.1, 123.9, 116.0, 38.5, 21.7. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₁H₁₉BrN₂O₃SNa 481.0198, 483.0177; Found 481.0201, 483.0177.



(containing rotamer)

4-Chloro-N-methyl-2-((4-methylphenyl)sulfonamido)-N-phenylbenzamide (9ha). The reaction was performed according to the general procedure used 214 mg (0.5 mmol) of **8ha**. Purification by column chromatography on silica gel using hexane/AcOEt (2/1 v/v) to give **9ha**.

White solid (167 mg, 81% yield; mp 150–153 °C, containing rotamer). IR (KBr) v: 3280, 3116, 3052, 2954, 2923, 2877, 1639, 1592, 1492, 1369, 1168, 1091, 941, 769, 700, 543 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 7.86 (d, *J* = 9.0 Hz, 1.5H), 7.77 (d, *J* = 9.0 Hz, 0.50H), 7.68 (br s, 0.75H), 7.56 (d, *J* = 8.4 Hz, 0.25H), 7.47 (dd, *J* = 7.2, 7.2 Hz, 0.5H), 7.42 (br s, 0.25H), 7.35 (ddd, *J* = 7.2, 7.2, 1.2 Hz, 0.25H), 7.31–7.28 (m, 3.5H), 7.20 (dd, *J* = 8.4, 1.2 Hz, 0.25H), 7.12–7.07 (m, 2.25H), 6.99 (dd, 8.4, 8.4 Hz, 0.75H), 6.90 (d, *J* = 7.8 Hz. 1.5H), 6.72 (d, *J* = 6.6 Hz, 0.75H), 3.51 (s, 2.25H), 2.84 (s, 0.75H), 2.39 (s, 0.75H), 2.38 (s, 2.25H); ¹³C {¹H} NMR (151 MHz, CDCl₃) δ 166.4, 166.1, 144.6, 144.5, 142.1, 142.0, 137.2, 137.0, 136.4, 135.6, 131.1, 130.9, 130.7, 130.6, 130.1, 130.0, 129.6, 128.7, 128.5, 127.8, 127.5, 127.46, 127.46, 126.6, 126.2, 126.1, 125.9, 124.6, 121.6, 116.9, 39.0, 37.4, 21.71, 21.68. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₁H₁₉ClN₂O₃SNa 437.0703, 439.0673; Found 437.0702, 439.0677.



6-Chloro-N-methyl-2-((4-methylphenyl)sulfonamido)-N-phenylbenzamide (9ia). The reaction was performed according to the general procedure used 214 mg (0.5 mmol) of **8ia**. Purification by column chromatography on silica gel using hexane/AcOEt (2/1 v/v) to give **9ia**.

Pale-yellow solid (163 mg, 79% yield; mp 164 °C). IR (KBr) v: 3147, 3089, 2985, 2946, 2921, 1621, 1583, 1492, 1326, 1164, 935, 767, 713, 563 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 9.43 (br s, 1H), 7.82 (d, *J* = 7.8 Hz, 2H), 7.69 (d, *J* = 1.8 Hz, 1H), 7.31 (d, *J* = 8.4 Hz, 2H), 7.12 (dd, *J* = 7.2, 7.2 Hz, 1H), 7.09 (dd, *J* = 7.8, 7.8 Hz, 2H), 6.59 (d, *J* = 8.4 Hz, 1H), 6.56 (d, *J* = 8.4 Hz, 1H), 6.37 (d, *J* = 7.2 Hz, 1H), 3.4 (s, 3H), 2.38 (s, 3H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 168.6, 144.4, 144.1, 138.8, 137.1, 137.0, 131.1, 130.0, 129.5, 127.6, 127.1, 126.3, 123.2, 122.5, 122.2, 38.6, 21.7. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₁H₁₉ClN₂O₃SNa 437.0703,

439.0673; Found 437.0708, 439.0677.



7-Chloro-N-methyl-2-((4-methylphenyl)sulfonamido)-N-phenylbenzamide (9ja). The reaction was performed according to the general procedure used 214 mg (0.5 mmol) of 8ja. Purification by column chromatography on silica gel using hexane/AcOEt (2/1 v/v) to give 9ja.

Pale-yellow oil (134 mg, 63% yield). IR (KBr) v: 3062, 3031, 2917, 2859, 2840, 1627, 1592, 1496, 1336, 1155, 1091, 935, 806, 703, 665, 499 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 7.77 (d, J = 8.4 Hz, 2H), 7.45 (br s, 1H), 7.36–7.09 (m, 9H), 6.95 (dd, J = 7.2, 7.2 Hz, 1H), 2.99 (s, 3H), 2.40 (s, 3H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 167.9, 144.03, 144.03, 143.8, 137.1, 135.3, 132.8, 131.43, 131.36, 129.5, 129.0, 128.9, 127.58, 127.58, 127.2, 126.7, 38.0, 21.6. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₁H₁₉ClN₂O₃SNa 437.0703, 439.0673; Found 437.0704, 439.0678.



N-Methyl-2-((4-methylphenyl)sulfonamido)-*N*-phenylnicotinamide (9ka). The reaction was performed according to the general procedure used 197 mg (0.5 mmol) of 8ka. Purification by column chromatography on silica gel using hexane/AcOEt (2/1 v/v) to give 9ka.

Pale-brown oil (70.7 mg, 37% yield). IR (KBr) v: 3218, 3087, 3037, 2925, 1650, 1581, 1494, 1280, 1141, 1085, 773, 566 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 9.58 (br s, 1H), 8.06 (br s 1H), 8.04 (d, *J* = 6.6 Hz, 2H), 7.27 (d, *J* = 7.8 Hz, 2H), 7.26–7.23 (m, 2H), 7.19 (dd, *J* = 7.2, 7.2 Hz, 1H), 7.004–6.992 (m, 1H), 6.998 (d, *J* = 7.2 Hz, 2H), 6.48 (br s, 1H), 3.48 (s, 3H), 2.39 (s, 3H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 168.2, 150.6, 149.4, 144.0, 143.8, 138.3, 137.5, 129.8, 129.3, 128.5, 127.5, 126.7, 116.7, 116.1, 38.7, 21.7. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₀H₁₉N₃O₃SNa 404.1045; Found 404.1043.



N-Isopropyl-2-((4-methylphenyl)sulfonamido)-*N*-phenylbenzamide (9ab). The reaction was performed according to the general procedure used 211 mg (0.5 mmol) of 8ab. Purification by column chromatography on silica gel using hexane/AcOEt (2/1 v/v) to give 9ab.

Pale-yellow solid (187 mg, 92% yield; mp 120–123 °C). IR (KBr) v: 3218, 3062, 3029, 2969, 2933, 2877, 1617, 1589, 1488, 1376, 1159, 1093, 761, 705, 565 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 9.18 (br s, 1H), 7.77 (d, *J* = 8.4 Hz, 2H), 7.60 (dd, *J* = 8.4, 0.6 Hz, 1H), 7.27 (d, *J* = 8.4 Hz, 2H), 7.10 (dd, *J* = 7.8, 7.8 Hz, 1H), 7.06 (dd, *J* = 7.2, 7.2 Hz, 1H), 7.02 (dd, *J* = 7.8, 7.8 Hz, 2H), 6.67 (d, *J* = 6.0 Hz, 1H), 6.57 (dd, *J* = 7.2, 7.2 Hz, 1H), 6.31 (br s, 2H), 4.94 (br s, 1H), 2.37 (s, 3H), 1.13 (d, *J* = 7.2 Hz, 6H); ¹³C {¹H} NMR (151 MHz, CDCl₃) δ 169.2, 143.9, 139.3, 137.7, 136.7, 130.4, 129.9, 129.7, 128.7, 127.6, 127.4, 125.7, 122.8, 121.7, 48.6, 21.6, 20.9. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₃H₂₄N₂O₃SNa 431.1405; Found 431.1403.



N-(4-Methoxybenzyl)-2-((4-methylphenyl)sulfonamido)-N-phenylbenzamide (9ac). The reaction was performed according to the general procedure used 250 mg (0.5 mmol) of 8ac. Purification by column chromatography on silica gel using hexane/AcOEt (2/1 v/v) to give 9ac.

Pale-yellow solid (201 mg, 83% yield; mp 128–130 °C). IR (KBr) v: 3237, 3073, 3045, 2996, 2948, 2836, 1621, 1585, 1488, 1380, 1245, 1162, 1031, 910, 754, 703, 565 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 9.47 (br s, 1H), 7.72 (dd, *J* = 8.4, 0.6 Hz, 1H), 7.59 (d, *J* = 8.4 Hz. 2H), 7.14–7.11 (m, 3H), 7.04 (dd, *J* = 7.8, 7.8 Hz, 1H), 6.97 (d, *J* = 8.4 Hz, 2H), 6.94 (dd, *J* = 7.8, 7.8 Hz, 2H), 6.85 (d, *J* = 8.4 Hz, 2H), 6.69 (d, *J* = 7.2 Hz, 1H), 6.59 (dd, *J* = 7.2, 7.2 Hz, 1H), 6.04 (d, *J* = 7.2 Hz, 2H), 4.95 (s, 2H), 3.80 (s, 3H), 2.25 (s, 3H); ¹³C {¹H} NMR (151 MHz, CDCl₃) δ 168.9, 159.2, 143.7, 142.5, 137.3, 137.1, 130.9, 130.5, 130.1, 129.7, 129.0, 128.6, 127.3, 127.2, 126.8, 124.7, 123.1, 122.6, 113.7, 55.3, 53.3, 21.4. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₈H₂₆N₂O₄SNa 509.1511; Found 509.1511.



N-Chloro-2-((4-methylphenyl)sulfonamido)-*N*-phenylbenzamide (9ad). The reaction was performed according to the general procedure used 214 mg (0.5 mmol) of 8ad. Purification by column chromatography on silica gel using hexane/AcOEt (2/1 v/v) to give 9ad.

Brown oil (126 mg, 50% yield). IR (KBr) v: 3208, 3079, 2956, 2913, 1627, 1585, 1486, 1361, 1166, 1089, 763, 715 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 9.27 (br s, 1H), 7.79 (d, *J* = 7.8 Hz, 2H), 7.65 (d, *J* = 7.8 Hz, 1H), 7.27 (d, *J* = 7.8 Hz, 2H), 7.21 (dd, *J* = 7.8, 7.8 Hz, 1H), 7.08 (d, *J* = 7.8 Hz, 1H), 6.97 (dd, *J* = 8.4, 8.4 Hz, 1H), 6.71–6.66 (m, 2H), 6.51 (s, 1H), 6.18 (d, *J* = 6.6 Hz, 1H), 3.39 (s, 3H), 2.34 (s, 3H); ¹³C {¹H} NMR (151 MHz, CDCl₃) δ 169.1, 145.4, 144.1, 137.32, 137.32, 134.7, 131.4, 129.96, 129.96, 130.0, 127.5, 127.1, 126.21, 126.21, 124.7, 123.3, 123.0, 38.6, 21.6. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₁H₁₉ClN₂O₃SNa 437.0703, 439.0673; Found 437.0698, 439.0671.



N-(*tert*-Butyl)-*N*-(3,5-dimethylphenyl)-2-((4-methylphenyl)sulfonamido)benzamide (9ae). The reaction was performed according to the general procedure used 232 mg (0.5 mmol) of 8ae. Purification by column chromatography on silica gel using hexane/AcOEt (2/1 v/v) to give 9ae.

White solid (317 mg, 70% yield; mp 149 °C). IR (KBr) v: 3166, 2979, 2960, 2921, 2863, 1617, 1587, 1486, 1367, 1267, 1160, 1093, 937, 759, 715 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 8.66 (br s, 1H), 7.85 (d, *J* = 8.4 Hz, 2H), 7.29 (d, *J* = 8.4 Hz, 2H), 7.28 (dd, *J* = 7.8, 0.6 Hz, 1H), 6.94 (ddd, *J* = 7.8, 7.8, 1.2 Hz, 1H), 6.79 (dd, *J* = 7.8, 1.2 Hz, 1H), 6.72 (s, 1H), 6.58 (ddd, *J* = 7.2, 7.2, 0.6 Hz, 1H), 6.42 (s, 2H), 2.40 (s, 3H), 2.12 (s, 6H), 1.49 (s, 9H); ¹³C {¹H} NMR (151 MHz, CDCl₃) δ 170.4, 143.7, 140.9, 138.1, 137.8, 135.6, 129.9, 129.5, 129.4, 128.8, 128.1, 127.8, 127.4, 122.2, 119.5, 59.5, 29.2, 21.7, 21.1. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₆H₃₀N₂O₃SNa 473.1875; Found 473.1877.



4-Methyl-*N***-(2-(morpholine-4-carbonyl)phenyl)benzenesulfonamide (9af).** The reaction was performed according to the general procedure used 187 mg (0.5 mmol) of **8af**. Purification by column chromatography on silica gel using hexane/AcOEt (2/1 v/v) to give **9af**.

Pale-yellow oil (136 mg, 76% yield). IR (KBr) v: 3216, 3064, 2965, 2921, 2857, 1619, 1596, 1490, 1338, 1164, 763, 721, 565 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 8.51 (br s, 1H), 7.65 (d, *J* = 7.8 Hz, 2H), 7.62 (dd, *J* = 8.4, 1.2 Hz, 1H), 7.36 (dd, *J* = 7.2, 7.2 Hz, 1H), 7.21 (d, *J* = 7.8 Hz, 2H), 7.09–7.06 (m, 2H), 3.61–3.11 (m, 8H), 2.36 (s, 3H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 168.4, 143.9, 137.0, 136.4, 131.3, 129.7, 127.8, 127.2, 125.0, 124.1, 123.7, 66.6, 48.3, 42.5, 21.5. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₁₈H₂₀N₂O₄SNa 383.1042; Found 383.1042.



N-(2-(Indoline-1-carbonyl)phenyl)-4-methylbenzenesulfonamide (9ag). The reaction was performed according to the general procedure used 203 mg (0.5 mmol) of 8ag. Purification by column chromatography on silica gel using hexane/AcOEt (2/1 v/v) to give 9ag.

Colorless oil (128 mg, 65% yield). IR (KBr) v: 3251, 3064, 3031, 2958, 2923, 2857, 1625, 1589, 1482, 1338, 1164, 759, 563 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 8.67 (s, 1H), 8.16 (br s, 1H), 7.73 (d, *J* = 7.2 Hz, 1H), 7.54 (d, *J* = 7.8 Hz, 2H), 7.42 (dd, *J* = 7.8, 7.8 Hz, 1H), 7.26–7.08 (m, 5H), 6.90 (d, *J* = 7.8 Hz, 2H), 3.43 (br s, 2H), 2.87 (br s, 2H), 2.19 (br s, 3H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 167.0, 143.6, 141.9, 136.6, 135.7, 131.9, 131.6, 129.44, 129.44, 127.1, 126.9, 125.6, 124.83, 124.83, 118.2, 115.5, 50.8, 28.1, 21.5. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₂H₂₀N₂O₃SNa 415.1092; Found 415.1095.



4-Methyl-*N***-(2-(1-methyl-1***H***-indole-3-carbonyl)phenyl)benzenesulfonamide (9ah).** The reaction was performed according to the general procedure used 209 mg (0.5 mmol) of **8ah**. Purification by column chromatography on silica gel using hexane/AcOEt (2/1 v/v) to give **9ah**.

Pale-yellow oil (272 mg, 67% yield). IR (KBr) v: 3205, 3054, 3029, 2921, 1606, 1521, 1365, 1164, 754, 561 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 9.62 (br s, 1H), 8.20 (d, *J* = 7.8 Hz, 1H), 7.72 (dd, *J* = 8.4, 1.2 Hz, 1H), 7.53 (dd, *J* = 7.8, 1.8 Hz, 1H), 7.48 (d, *J* = 8.4 Hz, 2H), 7.45 (ddd, *J* = 7.8, 7.8, 1.8 Hz, 1H), 7.37–7.32 (m, 3H), 7.16 (ddd, *J* = 7.8, 7.8, 1.2 Hz, 1H), 7.09 (s, 1H), 6.79 (d, *J* = 7.8 Hz, 2H), 3.80 (s, 3H), 2.04 (s, 3H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 190.8, 143.1, 138.5, 137.4, 137.1, 136.2, 132.1, 130.6, 130.3, 129.2, 127.3, 127.0, 124.1, 124.03, 123.95, 123.1, 122.7, 115.8, 109.8, 33.7, 21.3. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₃H₂₀N₂O₃SNa 427.1092; Found 417.1092.



N-(2-(1*H*-Indole-3-carbonyl)phenyl)-4-methylbenzenesulfonamide (9ai). The reaction was performed according to the general procedure used 202 mg (0.5 mmol) of 8ai. Purification by column chromatography on silica gel using hexane/AcOEt (2/1 v/v) to give 9ai.

Pale-brown (138 mg, 71% yield). IR (KBr) v: 3338, 3122, 3060, 2923, 2867, 1606, 1488, 1428, 1386, 1330, 1195, 1160, 923, 754, 719, 561 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 9.69 (s, 1H), 9.56 (br s, 1H), 8.22–8.20 (m, 1H), 7.71 (dd, J = 8.4, 1.2 Hz, 1H), 7.53 (dd, J = 7.8, 1.8 Hz, 1H), 7.47 (ddd, J = 7.8, 7.8, 1.2 Hz, 1H), 7.444–7.430 (m, 1H), 7.437 (d, J = 8.4 Hz, 2H), 7.31–7.29 (m, 2H), 7.17 (d, J = 3.0 Hz, 1H), 7.16 (ddd, J = 7.8, 7.8, 0.6 Hz, 1H), 6.74 (d, J = 7.8 Hz, 2H), 2.03 (s, 3H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 191.6, 143.8, 136.7, 136.4, 135.41, 135.37, 132.2, 130.8, 130.6, 129.5, 127.2, 126.1, 124.7, 124.27, 124.27, 123.1, 122.2, 116.8, 112.0, 21.3. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₂H₁₈N₂O₃SNa 413.0936; Found 413.0936.



4-Methyl-*N***-(2-(2-methyl-1***H***-indole-3-carbonyl)phenyl)benzenesulfonamide (9aj).** The reaction was performed according to the general procedure used 209 mg (0.5 mmol) of **8aj**. Purification by column chromatography on silica gel using hexane/AcOEt (2/1 v/v) to give **9aj**.

Pale-brown oil (55.1 mg, 50% yield). IR (KBr) v: 3336, 3056, 2921, 1606, 1486, 1378, 1159, 763, 561 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 10.00 (s, 1H), 8.90 (br s,1H), 7.80 (dd, *J*=9.0, 1.2 Hz, 1H), 7.57 (d, *J*=8.4 Hz, 2H), 7.47 (ddd, *J* = 7.8, 7.8, 1.2 Hz, 1H), 7.46 (d, *J* = 7.8 Hz, 1H), 7.30 (d, *J* = 8.4 Hz, 1H), 7.14 (ddd, *J* = 7.8, 7.8, 0.6 Hz, 1H), 7.06 (ddd, *J* = 7.2, 7.2, 1.2 Hz, 1H), 6.95 (ddd, *J* = 7.8, 7.8, 0.6 Hz, 1H), 6.89 (d, *J* = 8.4 Hz, 2H), 6.76 (d, *J* = 7.8 Hz, 1H), 2.42 (s, 3H), 2.03 (s, 3H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 193.4, 144.7, 143.8, 137.3, 135.9, 134.6, 132.9, 132.4, 130.0, 129.6, 127.2, 127.1, 124.2, 123.4, 122.7, 121.6, 120.9, 114.0, 110.9, 21.3, 14.6. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₃H₂₀N₂O₃SNa 427.1092; Found 427.1089.



N-(2-(5-Methoxy-1*H*-indole-3-carbonyl)phenyl)-4-methylbenzenesulfonamide (9ak). The reaction was performed according to the general procedure used 435 mg (0.5 mmol) of 8ak. Purification by column chromatography on silica gel using hexane/AcOEt (2/1 v/v) to give 9ak.

Brown oil (86.4 mg, 41% yield). IR (KBr) v: 3359, 3064, 2996, 2935, 2832, 1594, 1486, 1380, 1272, 1159, 1089, 811, 717, 561 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 9.60 (s, 1H), 8.95 (br s, 1H), 7.72 (s, 1H), 7.70 (d, *J* = 7.8 Hz, 1H), 7.52 (d, *J* = 6.6 Hz, 1H), 7.48 (d, *J* = 7.2 Hz, 2H), 7.45 (dd, *J* = 7.2, 7.2 Hz, 1H), 7.31 (d, *J* = 7.8 Hz, 1H), 7.18–7.14 (m, 2H), 6.95 (d, *J* = 6.6 Hz, 1H), 6.80 (d, *J* = 7.2 Hz, 2H), 3.90 (s, 3H), 2.07 (s, 3H); ¹³C {¹H} NMR (151 MHz, CDCl₃) δ 191.4, 156.7, 156.7, 143.5, 137.0, 135.9, 135.0, 132.1, 131.0, 130.6, 130.4, 129.4, 127.3, 127.1, 124.3, 124.0, 117.0, 114.8, 112.5, 103.7, 55.9, 21.4. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₃H₂₀N₂O₄SNa 443.1042; Found 443.1039.



N-(2-(5-Chloro-1*H*-indole-3-carbonyl)phenyl)-4-methylbenzenesulfonamide (9al). The reaction was performed according to the general procedure used 219 mg (0.5 mmol) of 8al. Purification by column chromatography on silica gel using hexane/AcOEt (2/1 v/v) to give 9al.

Brown oil (153 mg, 72% yield). IR (KBr) v: 3289, 3031, 2923, 1608, 1517, 1326, 1160, 883, 761, 561 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 9.635 (s, 1H), 9.635 (br s, 1H), 8.14 (d, *J* = 1.2 Hz, 1H), 7.68 (d, *J* = 8.4 Hz, 1H), 7.52 (d, *J* = 7.2 Hz, 1H), 7.47 (dd, *J* = 7.8 Hz, 1H), 7.44 (d, *J*= 7.8 Hz, 2H), 7.36 (d, *J* = 8.4 Hz, 1H), 7.23 (d, *J* = 7.8 Hz, 1H), 7.21 (s, 1H), 7.17 (dd, *J* = 7.2, 7.2 Hz, 1H), 6.79 (d, *J* = 7.8 Hz, 2H), 2.04 (s, 3H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 191.3, 143.9, 136.8, 136.0, 135.4, 134.7, 132.4, 130.7, 130.2, 129.5, 128.9, 127.2, 124.7, 124.6, 124.3, 121.77, 121.77, 116.4, 113.0, 21.3. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₂H₁₇ClN₂O₃SNa 447.0546, 449.0517; Found 447.0551, 449.0514.



N-(2-(5-Bromo-1*H*-indole-3-carbonyl)phenyl)-4-methylbenzenesulfonamide (9am). The reaction was performed according to the general procedure used 242 mg (0.5 mmol) of 8am. Purification by column chromatography on silica gel using hexane/AcOEt (2/1 v/v) to give 9am.

Brown oil (125 mg, 53% yield). IR (KBr) v: 3255, 3029, 2923, 2850, 1608, 1517, 1428, 1328, 1159, 761, 719, 559 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 9.61 (s, 1H), 8.86 (br s, 1H), 8.28 (s, 1H), 7.73 (d, *J* = 7.8 Hz, 1H), 7.540–7.528 (m, 1H), 7.534 (d, *J* = 7.2 Hz, 2H), 7.48 (dd, *J* = 7.2, 7.2 Hz, 1H), 7.42 (d, *J* = 5.4 Hz, 1H), 7.32–7.26 (m, 2H), 7.16 (dd, *J* = 6.0, 6.0 Hz, 1H), 6.88 (d, *J* = 7.2 Hz, 2H), 2.10 (s, 3H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 191.3, 143.9, 136.9, 135.7, 135.5, 135.0, 132.5, 130.8, 130.1, 129.5, 127.7, 127.2, 124.86, 124.86, 124.6, 124.2, 116.6, 116.4, 113.4, 21.4. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₂H₁₇BrN₂O₃SNa 491.0041, 493.0021; Found 491.0041, 493.0020.



N-(2-(4-Chloro-1*H*-indole-3-carbonyl)phenyl)-4-methylbenzenesulfonamide (9an). The reaction was performed according to the general procedure used 219 mg (0.5 mmol) of 8an. Purification by column chromatography on silica gel using hexane/AcOEt (2/1 v/v) to give 9an.

Brown oil (43.9 mg, 21% yield). IR (KBr) v: 3212, 3118, 3064, 3029, 2923, 2854, 1608, 1488, 1338, 1159, 1089, 734, 565 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 10.89 (s, 1H), 8.91 (br s, 1H), 7.76 (d, J = 8.4 Hz, 1H), 7.72 (d, J = 7.8 Hz, 2H), 7.55 (d, J = 7.2 Hz, 1H), 7.45 (dd, J = 7.8, 7.8 Hz, 1H), 7.36 (br s, 1H), 7.22–7.20 (m, 3H), 7.15 (d, J = 7.8 Hz, 2H), 6.99 (dd, J = 7.8, 7.8 Hz, 1H), 2.33 (s, 3H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 193.3, 143.9, 139.5, 137.6, 136.7, 134.02, 133.99, 131.8, 129.8, 127.5, 126.9, 126.8, 124.7, 123.9, 123.5, 122.9, 120.5, 117.9, 110.6, 21.7. HRMS (ESI) m/z: [M+Na]⁺ Calcd for C₂₂H₁₇ClN₂O₃SNa 447.0546, 449.0517; Found 447.0544, 449.0518.



N-(2-(6-Chloro-1*H*-indole-3-carbonyl)phenyl)-4-methylbenzenesulfonamide (9ao). The reaction was performed according to the general procedure used 219 mg (0.5 mmol) of **8ao**. Purification by column chromatography on silica gel using hexane/AcOEt (2/1 v/v) to give **9ao**.

Pale-brown oil (72.9 mg, 34% yield). IR (KBr) v: 3272, 3064, 2969, 2923, 2854, 1608, 1515, 1330, 1160, 1089, 879, 761, 727, 566 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 9.66 (s, 1H), 9.59 (br s, 1H), 8.09 (d, *J* = 8.4 Hz, 1H), 7.68 (dd, *J* = 8.4, 1.2 Hz, 1H), 7.52 (dd, *J* = 7.8, 1.2 Hz, 1H), 7.47 (dd, *J* = 7.2, 7.2 Hz, 1H), 7.45 (d, *J* = 8.4 Hz, 2H), 7.37 (d, *J* = 1.2 Hz, 1H), 7.24 (dd, *J* = 7.8, 1.8 Hz. 1H), 7.18 (d, *J* = 2.4 Hz, 1H), 7.16 (ddd, *J* = 7.8, 7.8, 1.2 Hz, 1H), 6.80 (d, *J* = 8.4 Hz, 2H), 2.06 (s, 3H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 191.4, 143.9, 136.82, 136.75, 135.6, 135.4, 132.5, 130.8, 130.1, 130.0, 129.5, 127.2, 124.66, 124.66, 124.1, 123.7, 123.2, 116.7, 111.9, 21.3. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₂H₁₇ClN₂O₃SNa 447.0546, 449.0517; Found 447.0544, 449.0522.



N-(2-(7-Chloro-1*H*-indole-3-carbonyl)phenyl)-4-methylbenzenesulfonamide (9ap). The reaction was performed according to the general procedure used 219 mg (0.5 mmol) of 8ap. Purification by column chromatography on silica gel using hexane/AcOEt (2/1 v/v) to give 9ap.

Pale-yellow oil (99.8 mg, 47% yield). IR (KBr) v: 3261, 3060, 2921, 2856, 1614, 1587, 1430, 1386, 1166, 1083, 759, 547 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 9.50 (s, 1H), 9.06 (br s, 1H), 8.09 (d, *J* = 8.4 Hz, 1H), 7.74 (d, *J* = 8.4 Hz, 1H), 7.54 (d, *J* = 7.8 Hz, 1H), 7.49 (dd, *J* = 7.8, 7.8 Hz, 1H), 7.46 (d, *J* = 7.8 Hz, 2H), 7.34 (d, *J* = 7.2 Hz. 1H), 7.27–7.24 (m,.2H), 7.18 (dd, *J* = 7.2, 7.2 Hz, 1H), 6.78 (d, *J* = 7.8 Hz, 2H), 2.06 (s, 3H); ¹³C {¹H} NMR (151 MHz, CDCl₃) δ 191.4, 143.4, 137.1, 135.9, 134.6, 133.5, 132.5, 130.5, 130.2, 129.4, 127.6, 127.4, 124.6, 124.5, 124.0, 123.7, 121.2, 118.1, 117.0, 21.3. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₂H₁₇ClN₂O₃SNa 447.0546, 449.0517; Found 447.0546, 449.0519.



N-(2-(1*H*-Indole-1-carbonyl)phenyl)-4-methylbenzenesulfonamide (9aq). The reaction was performed according to the general procedure used 202 mg (0.5 mmol) of 8aq. Purification by column chromatography on silica gel using hexane/AcOEt (3/1 v/v) to give 9aq.

Pale-yellow solid (121 mg, 62% yield). IR (KBr) v: 3278, 3151, 3110, 3064, 3050, 3029, 2973, 2917, 1652, 1600, 1452, 1338, 1162, 767, 559 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 8.54 (s, 1H), 8.20 (d, *J* = 8.4 Hz, 1H), 7.82 (dd, *J* = 8.4, 1.2 Hz, 1H), 7.58–7.56 (m, 2H), 7.45 (d, *J* = 8.4 Hz, 2H), 7.38 (ddd, *J* = 7.8, 7.8, 1.2 Hz, 1H), 7.35–7.32 (m, 2H), 7.24 (ddd, *J* = 7.8, 7.8, 1.2 Hz, 1H), 6.77 (d, *J* = 7.8 Hz, 2H), 6.63 (d, *J* = 3.6 Hz, 1H), 6.46 (d, *J*= 3.0 Hz, 1H), 2.05 (s, 3H); ¹³C {¹H} NMR (151 MHz, CDCl₃) δ 167.4, 144.0, 137.4, 135.74, 135.66, 133.1, 130.7, 130.3, 129.5, 127.4, 127.0, 126.6, 126.0, 125.4, 125.0, 124.6, 121.0, 116.6, 108.9, 21.4. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₂H₁₈N₂O₃SNa 413.0936; Found 413.0937.



4-Methyl-*N***-(2-(1-methylindoline-5-carbonyl)phenyl)benzenesulfonamide (9ar).** The reaction was performed according to the general procedure used 210 mg (0.5 mmol) of **8ar**. Purification by column chromatography on silica gel using hexane/AcOEt (1/1 v/v) to give **9ar**.

Pale-yellow oil (113 mg, 56% yield). IR (KBr) v: 3174, 3056, 2952, 2921, 2836, 1589, 1338, 1162 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 9.49 (s, 1H), 7.73 (dd, *J* = 8.4, 1.2 Hz. 1H), 7.49 (d, *J* = 8.4 Hz, 2H), 7.44 (ddd, *J* = 7.8, 7.8, 1.2 Hz, 1H), 7.33 (dd, *J* = 7.8, 1.2 Hz, 1H), 7.26 (s, 1H), 7.12–7.08 (m, 2H), 6.96 (d, *J* = 7.8 Hz, 2H), 6.20 (d, *J* = 9.0 Hz, 1H), 3.55 (t, *J* = 8.4 Hz, 2H), 3.00 (t, *J* = 8.4 Hz, 2H), 2.88 (s, 3H), 2.18 (s, 3H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 195.3, 157.2, 143.3, 137.8, 136.0, 133.8, 132.2, 131.8, 129.6, 129.5, 129.3, 127.3, 126.5, 125.9, 124.1, 123.7, 103.8, 55.0, 34.2, 27.7, 21.5. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₃H₂₂N₂O₃SNa 429.1249; Found 429.1246.



4-Methyl-*N***-(2-(1-methyl-1***H***-pyrrole-2-carbonyl)phenyl)benzenesulfonamide (9as).** The reaction was performed according to the general procedure used 184 mg (0.5 mmol) of **8as**. Purification by column chromatography on silica gel using hexane/AcOEt (2/1 v/v) to give **9as**.

Pale-yellow oil (120 mg, 68% yield). IR (KBr) v: 3216, 3064, 2950, 2925, 1608, 1594, 1488, 1375, 1166, 754, 723, 541 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 9.46 (s, 1H), 7.69 (dd, *J* = 8.4, 0.6 Hz, 1H), 7.53 (dd, *J* = 7.8, 1.8 Hz, 1H), 7.48 (d, *J* = 8.4 Hz, 2H), 7.45 (ddd, *J* = 7.8, 7.8, 1.2 Hz, 1H), 7.11 (ddd, *J* = 7.8, 7.8, 1.2 Hz, 1H), 6.95 (d, *J* = 8.4 Hz, 2H), 6.88 (t, *J* = 1.8 Hz, 1H), 6.18 (dd, *J* = 4.2, 1.8 Hz, 1H), 6.04 (dd, *J* = 4.2, 2.4 Hz, 1H), 3.94 (s, 3H), 2.20 (s, 3H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 186.1, 143.6, 137.5, 135.9, 132.5, 132.3, 131.4, 130.3, 129.6, 129.4, 127.2, 124.2, 124.0, 123.9, 108.3, 37.7, 21.5. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₁₉H₁₈N₂O₃SNa 377.0936; Found 377.0939.



2-([1,1'-Biphenyl]-4-sulfonamido)-*N***-methyl-***N***-phenylbenzamide (9la).** The reaction was performed according to the general procedure used 228 mg (0.5 mmol) of **8la**. Purification by column chromatography on silica gel using hexane/AcOEt (2/1 v/v) to give **9la**.

Pale-yellow solid (172 mg, 78% yield; mp 173–174 °C). IR (KBr) v: 3176, 3087, 3050, 2969, 2925, 1631, 1592, 1488, 1402, 1371, 1170, 1097, 761, 701, 566 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 9.43 (br s, 1H), 7.99 (d, *J* = 8.4 Hz, 2H), 7.70–7.68 (m, 3H), 7.50 (d, *J* = 6.6 Hz, 2H), 7.43 (dd, *J* = 7.8, 7.8 Hz, 2H), 7.39 (dd, *J* = 7.2, 7.2 Hz. 1H), 7.19 (dd, *J* = 7.8, 7.8 Hz, 1H), 7.03–7.02 (m, 3H), 6.68 (d, *J* = 6.6 Hz, 1H), 6.04 (dd, *J* = 7.2, 7.2 Hz, 1H), 6.45 (br s, 2H), 3.42 (s, 3H); ¹³C {¹H} NMR (151 MHz, CDCl₃) δ 169.5, 146.2, 144.5, 139.4, 137.5, 131.04, 130.04, 130.1, 129.4, 129.2, 128.7, 128.1, 127.8, 127.4, 126.9, 126.4, 124.9, 123.1, 122.4, 38.6. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₆H₂₂N₂O₃SNa 465.1249; Found 465.1254.

Scheme S3. Control experiments.



To a solution of **8aa** (1.0 mmol) in DMSO (5 mL, 0.2 M) were added *tert*-BuOK (337 mg, 3.0 mmol, 3.0 equiv.) and TEMPO (1.56 g, 10 mmol, 10 equiv.) under air condition. The mixture was stirred at room temperature until the complete disappearance of starting materials as indicated by TLC. After H₂O (20 mL) was added to the mixture, the whole was extracted with AcOEt (3 x 20 mL) and washed with brine (5 x 20 mL). The combined organic layer was dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography using hexane/AcOEt (2/1 v/v) to give **9aa** (290 mg, 76%).



To a solution of **8aa** (1.0 mmol) in DMSO (5 mL, 0.2 M) were added *tert*-BuOK (337 mg, 3.0 mmol, 3.0 equiv.) and BHT (2.20 g, 10 mmol, 10 equiv.) under air condition. The mixture was stirred at room temperature until the complete disappearance of starting materials as indicated by TLC. After H₂O (20 mL) was added to the mixture, the whole was extracted with AcOEt (3 x 20 mL) and washed with brine (5 x 20 mL). The combined organic layer was dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography using hexane/AcOEt (2/1 v/v) to give **9aa** (193 mg, 51%).



N-(2-(1H-Indole-3-carbonyl)phenyl)-N-tosylformamide (11ai).

Pale-yellow solid (12.6 mg, 6% yield). IR (KBr) v: 3342, 3185, 3056, 2923, 2852, 1610, 1436, 1340, 1159, 914, 750, 676, 565 cm⁻¹. ¹H NMR (600 MHz, DMSO-*d*₆) δ 12.40 (s, 1H), 10.63 (s, 1H), 8.22 (d, *J* = 3.0 Hz, 1H), 8.17 (d, *J* = 7.2 Hz, 1H), 7.69 (d, *J* = 7.8 Hz, 1H), 7.64 (d, *J* = 8.4 Hz, 2H), 7.57–7.54 (m, 2H), 7.37 (d, *J* = 7.8 Hz, 2H), 7.33–7.25 (m, 3H), 7.11 (d, *J* = 8.4 Hz, 1H), 2.36 (s, 3H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 197.6, 187.0, 144.6, 141.7, 136.6, 136.34, 136.34, 135.9, 134.8, 130.1, 127.5, 127.3, 125.3, 124.9, 123.8, 122.7, 122.4, 118.6, 114.3, 112.0, 21.7. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₃H₁₈N₂O₄SNa 441.0885; Found 441.0885.

Scheme S4. Follow up chemistry.



2-Amino-N-methyl-N-phenylbenzamide (12aa) ^[3c]. To a solution of **9aa** (38.1 mg, 0.1 mmol) in DCE (1 mL, 0.1 M) was added TfOH (0.5 mL). The mixture was stirred at 100 °C in oil bath for 1 h. After the whole was cooled to room temperature, the resulting mixture was quenched with sat. NaHCO₃ (5 mL) and extracted with AcOEt (3 x 20 mL). The combined organic layer was washed with brine (20 mL), dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography using hexane/AcOEt (3/1 v/v) to give **12aa**.

Pale-yellow oil (19.7 mg, 87% yield). IR (KBr) v: 3434, 3367, 3062, 3035, 2925, 2854, 1619, 1585, 1492, 1371, 1159, 1027, 752, 700, 586 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 7.22 (dd, *J* = 7.8, 7.8 Hz, 2H), 7.12 (dd, *J* = 7.8, 7.8 Hz, 1H), 7.06 (d, *J* = 8.4 Hz, 2H), 6.97 (ddd, *J* = 8.4, 7.2, 1.2 Hz, 1H), 6.71 (dd, *J* = 7.8, 1.8 Hz, 1H), 6.61 (dd, *J* = 8.4, 1.2 Hz, 1H), 6.31 (ddd, *J* = 7.8, 7.8, 0.6 Hz, 1H), 4.66 (br s, 2H), 3.48 (s, 3H); ¹³C {¹H} NMR (151 MHz, CDCl₃) δ 171.2, 147.0, 145.1, 130.6, 129.8, 129.2, 126.5, 126.4, 119.8, 116.7, 116.5, 38.1. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₁₄H₁₄N₂OSNa 249.1004; Found 249.1004.



2-Amino-*N***-methyl-***N***-(4-tosylphenyl)benzamide (13aa)** ^[3c]**. 9aa** (38.1 mg, 0.1 mmol) was stirred at 100 °C in oil bath under solvent-free condition. Then, TfOH (0.5 mL) was added to **9aa** and the mixture was stirred for

1 minute. After the whole was cooled down to room temperature, the mixture was quenched with sat. NaHCO₃ (5 mL) and extracted with AcOEt (3 x 10 mL). The combined organic layer was washed with brine (10 mL), dried over Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography using hexane/AcOEt (1/1 v/v) to give 12aa (8.2 mg, 36%) and 13aa.

Pale-yellow solid (16.8 mg, 44% yield; mp 162–164 °C). IR (KBr) v: 3467, 3369, 3089, 3062, 2975, 2923, 2854, 1635, 1616, 1583, 1490, 1355, 1153, 1099, 754, 588 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 7.77–7.75 (m, 4H), 7.28 (d, *J* = 7.8 Hz, 2H), 7.15 (d, *J* = 8.4 Hz, 2H), 7.01 (ddd, *J* = 7.8, 7.8, 1.2 Hz, 1H), 6.63 (dd, *J* = 7.8, 1.2 Hz, 2H), 6.30 (ddd, J = 7.8, 7.8, 0.6 Hz. 1H), 4.69 (br s, 2H), 3.45 (s, 3H), 2.40 (s, 3H); ${}^{13}C{}^{1}H$ NMR (151) MHz, CDCl₃) δ 171.4, 149.4, 147.3, 144.4, 138.9, 138.5, 131.4, 130.1, 129.7, 128.7, 127.7, 126.5, 118.5, 117.1, 116.8, 37.8, 21.7. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₁H₂₀N₂O₃SNa 403.1092; Found 403.1097.



9ag (1.18 g, 3.0 mmol) was stirred at 100 °C in oil bath under solvent-free condition. Then, TfOH (1.5 mL) was added to **9ag** and the mixture was stirred for 1 minute. After the whole was cooled down to room temperature, the mixture was quenched with sat. NaHCO₃ (5 mL) and extracted with AcOEt (3 x 10 mL). The combined organic layer was washed with brine (10 mL), dried over Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography using hexane/AcOEt (2/1 v/v) ^[3c].



12ag

(2-Aminophenyl)(indolin-1-yl)methanone (12ag).

Pale-yellow solid (211 mg, 30% yield; 138-139 °C). IR (KBr) v: 3469, 3372, 3031, 2954, 2894, 2859, 1635, 1579, 1479, 1400, 763 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 7.56 (br s, 1H), 7.25–7.20 (m, 3H), 7.13 (dd, J =7.8, 7.8 Hz, 1H), 7.02 (dd, J = 7.2, 7.2 Hz, 1H), 6.77 (d, J = 7.8 Hz, 1H), 6.73 (dd, J = 7.2, 7.2 Hz, 1H), 4.11 (t, J = 7.8 Hz, 2H), 3.51 (br s, 2H), 3.11 (t, J = 7.2 Hz, 2H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 169.0, 145.8, 142.7, 132.8, 131.5, 128.4, 127.4, 125.1, 124.1, 122.8, 120.6, 117.7, 117.2, 50.7, 28.3. HRMS (ESI) m/z:

[M+Na]⁺ Calcd for C₁₅H₁₄N₂ONa 261.1004; Found 261.1008.



(2-Aminophenyl)(5-tosylindolin-1-yl)methanone (13ag).

Brown oil (590 mg, 50% yield). IR (KBr) v: 3467, 3367, 3062, 3025, 2958, 2921, 2854, 1619, 1585, 1479, 1375, 1145, 1087, 754, 661, 584 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 7.75 (d, *J* = 7.8 Hz, 2H), 7.68 (s, 1H), 7.66 (d, *J* = 9.0 Hz, 1H), 7.63 (d, *J* = 8.4 Hz, 1H), 7.23 (d, *J* = 7.8 Hz, 2H), 7.144 (dd, *J* = 7.8, 7.8 Hz, 1H), 7.138 (d, *J* = 7.2 Hz, 1H), 6.69 (d, *J* = 7.8 Hz, 1H), 6.64 (dd, *J* = 7.8, 7.8 Hz, 1H), 4.56 (br s, 2H), 4.05 (t, *J* = 8.4 Hz, 2H), 3.04 (t, *J* = 8.4 Hz, 2H), 2.33 (s, 3H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 169.6, 146.9, 146.2, 143.8, 138.9, 136.2, 134.0, 131.8, 129.8, 128.0, 127.6, 127.2, 124.0, 118.8, 117.1, 116.9, 116.8, 50.8, 27.5, 21.4. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₂H₂₀N₂O₃SNa 415.1092; Found 415.1094.



5-Tosyl-5,6-dihydro-11*H***-indolo**[**2,3-***b*]**quinolin-11-one (14)** ^[4]. To a solution of **9ai** (195 mg, 0.5 mmol) in DCE (5 mL, 0.1 M) was added MnO₂ (435 mg, 10 equiv., 5 mmol). The mixture was stirred at 100 °C in oil bath for 22 h. After the whole was cooled to room temperature, the mixture was filtered with celite pad and concentrated *in vacuo*. The residue was purified by silica gel column chromatography using hexane/AcOEt (2/1 v/v) to give 14.

Pale-yellow solid (152 mg, 78% yield; 178–180 °C). IR (KBr) v: 3156, 3089, 2884, 1623, 1596, 1498, 1382, 1172, 779, 667 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 10.05 (br s, 1H), 8.49 (d, *J* = 8.4 Hz, 1H), 8.379 (d, *J* = 7.8 Hz, 1H), 7.65 (ddd, *J* = 9.0, 7.2, 1.8 Hz, 1H), 7.55 (d, *J* = 7.8 Hz, 1H), 7.48 (dd, *J* = 7.8, 7.8 Hz, 1H), 7.39 (dd, *J* = 7.2, 7.2 Hz, 1H), 7.35 (dd, *J* = 7.8, 7.8 Hz, 1H), 7.23 (d, *J* = 8.4 Hz, 2H), 7.00 (d, *J* = 7.8 Hz, 2H), 2.24 (s, 3H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 175.0, 146.5, 141.6, 136.9, 133.6, 132.1, 131.6, 130.1, 128.0, 126.95, 126.85, 126.6, 124.7, 123.0, 122.7, 122.1, 121.9, 111.3, 107.0, 21.7. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₂H₁₆N₂O₃SNa 411.0779; Found 411.0779.



5H,6H-Quinindolin-11-one (4) ^[1a, 6]. To a solution of **14** (116.5 mg, 0.3 mmol) in DMSO (1.5 mL, 0.2 M) was added *t*BuOK (101 mg, 3.0 equiv., 0.9 mmol). The mixture was stirred at room temperature for 1 h. After the mixture was quenched with H₂O (10 mL), the whole was extracted with AcOEt (3 x 10 mL) and washed with brine (10 mL). The combined organic layer was dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography using CHCl₃/MeOH (6/1 v/v) to give **4**.

Pale-yellow solid (41 mg, 58% yield; mp > 300 °C). IR (KBr) v: 3274, 3095, 3048, 2965, 1617, 1411, 1197, 740 cm⁻¹. ¹H NMR (600 MHz, DMSO- d_6) δ 12.16 (br s, 1H), 11.53 (br s, 1H), 8.29 (d, J = 7.8 Hz, 1H), 8.18 (d, J = 7.2 Hz, 1H), 7.64–7.63 (m. 2H), 7.47 (d, J = 7.8 Hz, 1H), 7.31–7.29 (m, 1H), 7.24 (dd, J = 7.8, 7.8 Hz, 1H), 7.19 (dd, J = 7.2, 7.2 Hz, 1H); ¹³C {¹H} NMR (151 MHz, DMSO- d_6) δ 172.3, 145.3, 138.3, 135.0, 130.8, 125.3, 123.8, 123.6, 122.7, 121.5, 120.9, 120.0, 117.5, 110.9, 101.8. HRMS (ESI) m/z: [M+Na]⁺ Calcd for C₁₅H₁₀N₂ONa 257.0691; Found 257.0694.



trans-6-Hydroxy-5-tosyl-5a,6-dihydroindolo[2,1-*b*]quinazolin-12(5*H*)-one (15) ^[7]. 9aq (39.0 mg, 0.1 mmol), iodobenzene diacetate (48.3 mg, 1.5 equiv., 0.15 mmol) and eosin-Y (2.1 mg, 3.0 mol%) in MeCN (2 mL) was stirred at room temperature under the irradiation of 8 W blue LED (448 nm) for 2 h. After H₂O (5 mL) was added to the mixture, the whole was extracted with AcOEt (3 x 10 mL). The combined organic layer was washed with brine (10 mL), dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography using hexane/AcOEt (3/1 v/v) to give **8la**.

Pale-yellow solid (16.9 mg, 42% yield). IR (KBr) v: 3361, 3064, 3048, 3029, 2960, 2927, 1644, 1484, 1427, 1359, 1168, 763, 674 cm⁻¹. ¹H NMR (600 MHz, CDCl₃) δ 7.98 (d, *J* = 7.8 Hz, 1H), 7.82 (d, *J* = 7.8 Hz, 1H), 7.69 (d, *J* = 7.8 Hz, 1H), 7.67 (dd, *J* = 8.4, 8.4 Hz, 1H), 7.51 (d, *J* = 8.4 Hz. 1H), 7.50 (d, *J* = 7.6 Hz, 1H), 7.29 (dd, *J* = 7.8, 7.8 Hz, 1H), 7.19 (dd, *J* = 7.2, 7.2 Hz, 1H), 6.86–6.83 (m, 5H), 5.50 (d, *J* = 4.8 Hz, 1H), 2.78 (br s, 1H), 2.25 (s, 3H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 159.2, 145.0, 140.5, 140.4, 134.2, 133.1, 130.3, 130.1,

129.5, 128.4, 128.2, 127.3, 127.0, 125.6, 125.2, 115.3, 84.4, 71.8, 21.6. HRMS (ESI) m/z: [M+Na]⁺ Calcd for C₂₂H₁₈N₂O₄SNa 429.0885; Found 429.0887.
Reference

- 1 (a) Heredia, M. D.; Guerra, W. D.; Barolo, S. M.; Fornasier, S. J.; Rossi, R. A.; Budén, M. E. *J. Org. Chem.* **2020**, *85*, 13481–13494. (b) Tokushige, K.; Abe, T. *J. Org. Chem.* **2024**, *89*, 10349–10354.
- 2 (a) Hodson, H. F.; Madge, D. J.; Slawin, A. N. Z.; Widdowson, D. A.; Williams, D. J. *Tetrahedron* 1994, 50, 1899–1906; (b) Arisawa, M.; Terada, Y.; Takahashi, K.; Nakagawa, M.; Nishida, A. J. Org. Chem. 2006, 71, 4255–4261; (c) Jayaraman, A.; Castro, L. C. M.; Fontaine, F.-G. Org. Process Res. Dev. 2018, 22, 1489–1499; (d) Sayyad, M.; Nanaji, Y.; Ghorai, M. K. J. Org. Chem. 2015, 80, 12659–12667; (e) Ramalingan, C.; Lee, I.-S.; Kwak, Y.-W. Chem. Pharm. Bull. 2009, 57, 591–596. ;(f) Keith, J. M. J. Org. Chem. 2010, 75, 2722–2725.
- 3 (a) Abe, T.; Suzuki, T.; Anada, M.; Matsunaga, S.; Yamada, K. Org. Lett. 2017, 19, 4275–4278; (b) Abe, T.; Hirao, S.; Yamashiro, T. Chem. Commun. 2020, 56, 10183–10186; (c) Abe, T.; Yamashiro, T.; Shimizu, K.; Sawada, D. Chem. Eur. J. 2022, 28, e202201113; (d) Abe, T.; Yamada, K. Org. Lett. 2018, 20, 1469–1472; (e) Yamada, K.; Mishima, N.; Saito, K.; Nishi, T. Tetrahedron 2021, 97, 132404.
- 4 Tokushige, K.; Abe, T. Chem. Eur. J. 2024, 30, e202302963.
- 5 Luca, O. R.; Wang, T.; Konezny, S. J.; Batista, V. S.; Crabtree, R. H. New J. Chem. 2011, 35, 998–999.
- 6 (a) Subbaraju, G. V.; Kavitha, J.; Rajasekhar, D.; Jimenez, J. I. J. Nat. Prod. 2004, 67, 461–462. (b) Wilkie, R. P.; Neal, A. R.; Johnson, C. A.; Voute, N.; Lancefield, C. S.; Stell, M. D.; Medda, F.; Makiyi, E. F.; Turner, E. M.; Ojo, O. S.; Slawin, A. M. Z.; Lebl, T.; Mullen, P.; Harrison, D. J.; Ireland, C. M.; Westwood, N. J. Chem. Commun. 2016, 52, 10747–10750.
- 7 Paul, A.; Sengupta, A.; Yadav, S. J. Org. Chem. 2023, 88, 9599-9614.

































































































































































































